抗血管生成药物联合免疫检查点抑制剂治疗非小细胞肺癌的作用机制及临床应用进展  

Research advances in mechanism and clinical application of anti-angiogenesis therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer

作　　者：邱鲁鹏 孙卓雅 赵晓[2] 焦顺昌[2] QIU Lupeng;SUN Zhuoya;ZHAO Xiao;JIAO Shunchang(Chinese PLA Medical School,Beijing 100853,China;Department of Oncology,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军医学院,北京100853 [2]解放军总医院第一医学中心肿瘤内科,北京100853

出　　处：《解放军医学院学报》2022年第12期1288-1292,1297,共6页Academic Journal of Chinese PLA Medical School

基　　金：国家自然科学基金项目(81972681)。

摘　　要：近年来,免疫治疗的兴起改变了非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗格局。抗血管生成药物使肿瘤局部血管正常化,有助于免疫效应细胞浸润,这一机制与免疫检查点抑制剂(immune checkpoint inhibitor,ICI)存在协同增效作用。本文将对抗血管生成药物与ICI联合治疗NSCLC的作用机制进行阐述,并对相关临床研究进行汇总分析,旨在为NSCLC患者提供更多的治疗选择。The use of immunotherapy has revolutionized the treatment of patients with non-small cell lung cancer(NSCLC)in recent years.Anti-angiogenic agents can induce tumor vessel normalization and promote the infiltration of immune effector cells,which may synergize with immune checkpoint inhibitors(ICIs).In this paper,the mechanisms of anti-angiogenic agents combined with ICIs are illustrated,and relevant clinical studies are summarized and analyzed,in order to provide more treatment options for NSCLC patients.

关 键 词：非小细胞肺癌 抗血管生成治疗 免疫检查点抑制剂 总生存期 安全性 

分 类 号：R734.2[医药卫生—肿瘤]